MoonLake Immunotherapeutics (MLTX) reported a Q4 loss Wednesday of $0.72 per diluted share, compared with a loss of $0.12 a year earlier.

Analysts polled by FactSet expected a loss of $0.62.

The company said it held cash, cash equivalents and short-term marketable debt securities of $448 million at the end of last year, compared with $493.9 million as of Sept. 30.